Estudio del estándar Passivhaus, aplicación y comparativa con el CTE

El estándar Passivhaus es un estándar de construcción de edificaciones, no sólo residenciales, que establece unos criterios generales de certificación en cuanto a demanda energética, consumo energético y estanqueidad del aire, además de otra serie de criterios y recomendaciones constructivas. No se trata de un estándar de carácter normativo, sino voluntario, que responde a una conciencia social en cuanto a eficiencia energética, que surgió en Alemania de modo experimental en 1991, de la mano de los profesores Bo Adamson y Wolfgang Feist. El objeto de este Trabajo Fin de Máster es contextualizar el estándar Passivhaus, definirlo, analizarlo, estudiar ejemplos de viviendas Passivhaus certificadas en España y comparar sus exigencias con las del CTE en materia de eficiencia energética. Se realiza un diseño de vivienda según el estándar Passivhaus, ubicada en Alicante, atendiendo a criterios de arquitectura pasiva así como específicos Passivhaus, y considerando los criterios de certificación. Los resultados obtenidos del diseño de la vivienda Passivhaus se comparan con los resultados de la misma vivienda realizados con los estándares del actual CTE, comparando diferentes aspectos de ambas soluciones, componentes constructivos, eficiencia energética, coste y tiempo de amortización, emisiones de CO2

Multi-GPU based on multicriteria optimization for motion estimation system.

Medical imaging has become an absolutely essential diagnostic tool for clinical practices; at present, pathologies can be detected with an earliness never before known. Its use has not only been relegated to the field of radiology but also, increasingly, to computer-based imaging processes prior to surgery. Motion analysis, in particular, plays an important role in analyzing activities or behaviors of live objects in medicine. This short paper presents several low-cost hardware implementation approaches for the new generation of tablets and/or smartphones for estimating motion compensation and segmentation in medical images. These systems have been optimized for breast cancer diagnosis using magnetic resonance imaging technology with several advantages over traditional X-ray mammography, for example, obtaining patient information during a short period. This paper also addresses the challenge of offering a medical tool that runs on widespread portable devices, both on tablets and/or smartphones to aid in patient diagnostics

Implementation of a low-cost mobile devices to support medical diagnosis

Medical imaging has become an absolutely essential diagnostic tool for clinical practices; at present, pathologies can be detected with an earliness never before known. Its use has not only been relegated to the field of radiology but also, increasingly, to computer-based imaging processes prior to surgery. Motion analysis, in particular, plays an important role in analyzing activities or behaviors of live objects in medicine. This short paper presents several low-cost hardware implementation approaches for the new generation of tablets and/or smartphones for estimating motion compensation and segmentation in medical images. These systems have been optimized for breast cancer diagnosis using magnetic resonance imaging technology with several advantages over traditional X-ray mammography, for example, obtaining patient information during a short period. This paper also addresses the challenge of offering a medical tool that runs on widespread portable devices, both on tablets and/or smartphones to aid in patient diagnostics

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective